WallStreetZenWallStreetZen

NYSEMKT: OSTX
Os Therapies Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Os Therapies earnings were -$13.3M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest OSTX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$3.9M, down 21.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, OSTX reported annual earnings of -$10.9M, with 37.5% growth.

OSTX earnings history

Current Revenue
$0.0
Current Earnings
-$13.3M
Current Profit Margin
0%

OSTX Return on Equity

Insufficient data to display

OSTX undefined

Current Company
-405%
Current Industry
-2.5%
OSTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when OSTX announces earnings.

OSTX undefined

Current Company
-1,412.11%
Current Industry
5.8%

OSTX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
OSTX-$10.07M-$13.27MN/A-$0.86
GANX-$20.23M-$20.93MN/A-$0.86
CBUS-$233.89M-$274.84MN/A-$10.61
ADVM-$128.80M-$153.16MN/A-$7.43
KLTO-$6.80M-$7.71MN/A-$0.36
View Top Biotech Stocks

Os Therapies Earnings Reports & History FAQ

What were Os Therapies's earnings last quarter?

Os Therapies (NYSEMKT: OSTX) reported Q1 2025 earnings per share (EPS) of -$0.18, up 28% year over year. Total OSTX earnings for the quarter were -$3.88 million. In the same quarter last year, Os Therapies's earnings per share (EPS) was -$0.25.

If you're new to stock investing, here's how to buy Os Therapies stock.

Is Os Therapies profitable or losing money?

As of the last Os Therapies earnings report, Os Therapies is currently losing money. Os Therapies's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$11.30 million, a 52.64% increase year over year.

What was OSTX's earnings growth in the past year?

As of Os Therapies's earnings date in Q2 2025, Os Therapies's earnings has grown year over year. OSTX earnings in the past year totalled -$13.27 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.